Department of Clinical Pathology and Microbiology, San Gallicano Dermatology Institute, Rome, Italy.
J Biol Regul Homeost Agents. 2009 Jul-Sep;23(3):155-64.
The level of CD81 cell surface expression, a cellular co-receptor for hepatitis C virus (HCV), is critical for productive HCV infection of host cells. In addition, the cross-linking of HCV-E2 protein to CD81 can alter the function of T and B lymphocytes as well as that of NK cells by interfering with the activation signalling pathway. The down-regulation of CD81 expression on peripheral blood lymphocytes (PBL) has been associated to effective therapy of HCV infection. The aim of the present study is to quantitatively assess the levels of CD81 expression in PBL from HCV-infected patients compared to subjects at high risk for HCV infection such as HIV-infected individuals or patients with Porphyria Cutanea Tarda (PCT). The expression of CD81 was quantified by flow-cytometry using Phycoerythrin-labelled standard beads. Determination of CD81 was performed on CD3+ and CD19+ lymphocytes from 34 healthy controls, 51 patients with HCV infection and different clinical outcomes [these included HCV-RNA-negative subjects (8), patients with chronic active hepatitis (16), recipients of liver transplantation under immunosuppressive therapy (12), a subgroup with concomitant HIV infection (9) or concomitant PCT (6)]. In addition, 60 HIV-infected subjects and 4 patients with PCT were studied. The putative role of inflammatory cytokines in modulating CD81 was explored in vitro by assessing the effect of IL-6 or IFN-gamma on cultured human hepatocytes. A significant increase of the CD81 expression was found on CD19+ lymphocytes in association with either HIV or HCV infection, as compared to the control group. Immunosuppressive therapy with FK506, subsequent to liver transplantation, restored CD81 expression at normal levels. Data gathered in vitro using the WRL 68 hepatocytic cell line confirmed that inflammatory cytokines can up-regulate CD81 expression in liver cell inclusion. Our data suggest that CD81 up-regulation can increase the risk of HCV infection, particularly in HIV-infected subjects. In addition, the results strongly suggest that the cytokines released by activated lymphocytes at sites of inflammation may play a part in up-regulating CD81 expression.
CD81 细胞表面表达水平是丙型肝炎病毒(HCV)的细胞共受体,对于宿主细胞的 HCV 感染具有关键作用。此外,HCV-E2 蛋白与 CD81 的交联可以通过干扰激活信号通路来改变 T 和 B 淋巴细胞以及 NK 细胞的功能。外周血淋巴细胞(PBL)中 CD81 表达的下调与 HCV 感染的有效治疗有关。本研究的目的是定量评估 HCV 感染患者的 PBL 中 CD81 表达水平,与 HCV 感染高危人群(如 HIV 感染者或卟啉病患者)进行比较。使用藻红蛋白标记的标准珠通过流式细胞术定量 CD81 的表达。在 34 名健康对照者、51 名 HCV 感染患者和不同临床结局[包括 HCV-RNA 阴性者(8 名)、慢性活动性肝炎患者(16 名)、接受免疫抑制治疗的肝移植受者(12 名)、合并 HIV 感染的亚组(9 名)或合并卟啉病(6 名)]的 CD3+和 CD19+淋巴细胞上进行 CD81 的测定。此外,还研究了 60 名 HIV 感染者和 4 名卟啉病患者。通过评估 IL-6 或 IFN-γ对培养的人肝细胞的影响,在体外探讨了炎症细胞因子在调节 CD81 中的作用。与对照组相比,在 HIV 或 HCV 感染时,在 CD19+淋巴细胞上发现 CD81 表达显著增加。肝移植后使用 FK506 进行免疫抑制治疗可使 CD81 表达恢复正常水平。使用 WRL 68 肝细胞系进行的体外数据证实,炎症细胞因子可上调肝细胞内的 CD81 表达。我们的数据表明,CD81 的上调可能增加 HCV 感染的风险,特别是在 HIV 感染者中。此外,研究结果强烈表明,炎症部位激活的淋巴细胞释放的细胞因子可能在上调 CD81 表达中发挥作用。